In conjunction with the American Uveitis Society
“Now the Future We Foresee”
Take a deep dive into the current research and challenges in the diagnosis and management of uveitis and ocular inflammatory diseases including new approaches, tools and standards of care.
Friday, Sept. 30
Russell W. Read, MD, PhD and Lucia Sobrin, MD
Program Planning Group
Wendy M. Smith, MD; Kathryn L. Pepple, MD, PhD; Edmund Tsui, MD; Stephanie M. Llop Santiago, MD; and Ann-Marie Lobo, MD
The mission of the 2022 Uveitis Subspecialty Day is to provide attendees with a comprehensive, state-of-the-art update on the diagnosis and management of uveitis.
The intended audience for this program includes general ophthalmologists, comprehensive ophthalmologists, uveitis specialists, other ophthalmologic subspecialists (cornea, retina, etc.), and allied health personnel who are involved in the management of patients with uveitis and ocular inflammatory diseases.
To provide attendees with comprehensive training in and an update on the challenges in the diagnosis and management of uveitis and various ocular inflammatory diseases, and to identify and discuss the current research that may lead to new management approaches and standards of care.
Upon completion of this activity, participants should be able to:
- Identify the various forms of ocular inflammatory diseases, including retinal vasculitis, and anterior, intermediate, and posterior uveitis.
- Construct a differential diagnosis for various forms of uveitis.
- Classify the principles of diagnosis for ocular inflammatory disorders in order to initiate appropriate disease-directed evaluations.
- Identify the important and appropriate role of immunomodulatory therapy for patients with specific ocular inflammatory diseases and also for patients with steroid-dependent inflammation.
- Describe the various gaps that currently exist in the management of uveitis and ocular inflammatory diseases.
- Describe potential new diagnostic and treatment modalities for uveitis and ocular inflammatory diseases, including selected therapeutic agents in development.